Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 2, 2013, Pages 161-166

  Nielsen, Stine E ^a   Schjoedt, Katrine J ^a   Rossing, Kasper ^a   Persson, Frederik ^a   Schalkwijk, Casper G ^b   Stehouwer, Coen D A ^b   Parving, Hans Henrik ^c,d   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Diabetes; diabetic nephropathy; endothelial dysfunction; inflammation

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID A PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; PLACEBO; SPIRONOLACTONE; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

DIABETES; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; INFLAMMATION;

ALBUMINURIA; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIUM; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SPIRONOLACTONE;

EID: 84878082474     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312460290     Document Type: Article

References (30)

1. Parving H-H, Mauer M, Ritz E Brenner & Rector's the kidney. 8 th ed.Boston, USA: WB Saunders, 2008, pp.1265-1298 Brenner BM, ed. Boston, USA: WB Saunders ; 2008: 1265-1298.
2. Astrup AS, Tarnow L, Pietraszek L, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008 ; 31: 1170-1176
3. Stehouwer CDA, Donker AJM. Urinary albumin excretion and cardiovascular disease risk in diabetes mellitus: Is endothelial dysfunction the missing link?. J Nephrol. 1993 ; 6: 72-92 (Pubitemid 23203425)
4. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes. 2002 ; 51: 1157-1165 (Pubitemid 34438363)
5. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J. 1988 ; 297: 1092-1095
6. Mathiesen ER, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J. 1999 ; 319: 24-25 (Pubitemid 29304341)
7. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007 ; 27: 144-152 (Pubitemid 46550312)
8. Hostetter TH, Rosenberg ME, Ibrahim HN, et al. Aldosterone in progressive renal disease. Semin Nephrol. 2001 ; 21: 573-579 (Pubitemid 33091939)
9. Schrier RW, Masoumi A, Elhassan E. Aldosterone: Role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol. 2010 ; 5: 1132-1140
10. Schrier RW. Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol. 2010 ; 6: 61
11. Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004 ; 47: 1936-1939 (Pubitemid 40110201)
12. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005 ; 68: 2829-2836 (Pubitemid 43251030)
13. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 2005 ; 28: 2106-2112 (Pubitemid 41242452)
14. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study. Diabet Med. 2012 ; 29: e184 - e190
15. Syngle A, Vohra K, Kaur L, et al. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scand J Rheumatol. 2009 ; 38: 15-22
16. Savoia C, Touyz RM, Amiri F, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008 ; 51: 432-439 (Pubitemid 351156429)
17. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest. 2008 ; 68: 731-738
18. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006 ; 70: 536-542 (Pubitemid 44141580)
19. Sibbald B, Roberts C. Understanding controlled trials. Crossover trials. Br Med J. 1998 ; 316: 1719 (Pubitemid 28254426)
20. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest. 1976 ; 36: 35-45
21. Sokoll LJ, Baum H, Collinson PO, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med. 2004 ; 42: 965-972
22. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003 ; 41: 64-68 (Pubitemid 36056793)
23. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004 ; 44: 362-368 (Pubitemid 38960662)
24. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudy. Diabetes. 2006 ; 55: 3550-3555 (Pubitemid 44923616)
25. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004 ; 91: 87-91 (Pubitemid 38296363)
26. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003 ; 63: 1791-1800 (Pubitemid 36513325)
27. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006 ; 17: 1362-1372
28. Godfrey V, Farquharson CA, Macdonald JE, et al. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol. 2007 ; 117: 282-284 (Pubitemid 46452773)
29. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006 ; 70: 2116-2123 (Pubitemid 44871374)
30. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 ; 52: 486-493